LEXX · Lexaria Bioscience Corp.

Lexaria Bioscience Corp. reported Q2 FY2026 results reflecting completion of Study GLP-1-H24-4, which drove meaningful improvements in loss metrics despite sharply lower revenue. Revenue fell 88.5% to $20 thousand from $174 thousand in the prior-year quarter, with gross profit matching revenue at $20 thousand for a 100% gross margin. This decline aligns with the company's pivot from prior licensing revenue streams, as management explores new collaborations, partnerships, and alliances to bolster capital resources.

Cash flow from operations used -$3.1 million, an improvement from -$4.2 million prior year, reflecting the narrower net loss tempered by study-related working capital swings. Capital expenditures rose modestly to $41 thousand from $25 thousand, yielding free cash flow of -$3.2 million. Since inception, the company has incurred significant operating and net losses, consistent with its R&D-focused strategy. Management's cash flow forecast indicates resources sufficient to fund operations through Q1 FY2027, amid ongoing pursuit of intellectual property expansions nationally and internationally.

Looking ahead, Lexaria anticipates continued operating losses and negative cash flows as planned R&D studies progress through 2026 and beyond. The inherent unpredictability of scientific discovery tempers expectations for new patent filings or issuances. Management emphasizes careful estimates in applying GAAP, which influence reported financials, while eyeing third-party arrangements to enhance liquidity. This positions the company to sustain its pipeline amid biotech sector challenges, with GLP-1-H24-4 completion marking a step toward cost discipline.